



US009173977B2

(12) **United States Patent**  
**Speck et al.**

(10) **Patent No.:** **US 9,173,977 B2**  
(45) **Date of Patent:** **\*Nov. 3, 2015**

(54) **COATING FORMULATIONS FOR SCORING OR CUTTING BALLOON CATHETERS**

(71) Applicant: **AngioScore, Inc.**, Fremont, CA (US)

(72) Inventors: **Ulrich Speck**, Berlin (DE); **Madeleine Caroline Berg**, Berlin (DE)

(73) Assignee: **AngioScore, Inc.**, Colorado Springs, CO (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 509 days.  
  
This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/628,627**

(22) Filed: **Sep. 27, 2012**

(65) **Prior Publication Data**

US 2013/0023817 A1 Jan. 24, 2013

**Related U.S. Application Data**

(63) Continuation of application No. PCT/EP2011/056179, filed on Apr. 18, 2011.

(30) **Foreign Application Priority Data**

Apr. 19, 2010 (EP) ..... 10160347

(51) **Int. Cl.**

**A61F 2/00** (2006.01)

**A61L 29/08** (2006.01)

**A61L 29/16** (2006.01)

**A61L 31/16** (2006.01)

**A61M 25/10** (2013.01)

(52) **U.S. Cl.**

CPC ..... **A61L 29/08** (2013.01); **A61L 29/16** (2013.01); **A61L 31/16** (2013.01); **A61M 25/10** (2013.01); **A61L 2300/416** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2,701,559 A 2/1955 Cooper  
2,854,983 A 10/1958 Baskin  
3,045,677 A 7/1962 Wallace  
3,467,101 A 9/1969 Fogarty et al.  
3,825,013 A 7/1974 Craven  
4,327,736 A 5/1982 Inoue  
4,456,011 A 6/1984 Warnecke  
4,483,340 A 11/1984 Fogarty et al.  
4,578,061 A 3/1986 Lemelson  
4,604,762 A 8/1986 Robinson  
4,637,396 A 1/1987 Cook  
4,649,922 A 3/1987 Wiktor  
4,723,549 A 2/1988 Wholey et al.  
4,796,629 A 1/1989 Grayzel  
4,838,853 A 6/1989 Parisi  
4,887,613 A 12/1989 Farr et al.

4,895,166 A 1/1990 Farr et al.  
4,921,484 A 5/1990 Hillstead  
4,942,788 A 7/1990 Farr et al.  
4,950,277 A 8/1990 Farr  
4,956,830 A 9/1990 Mock et al.  
4,966,604 A 10/1990 Reiss  
4,969,458 A 11/1990 Wiktor  
4,976,711 A 12/1990 Parins et al.  
4,986,807 A 1/1991 Farr  
4,986,830 A 1/1991 Owens et al.  
4,998,539 A 3/1991 Delsanti  
5,003,918 A 4/1991 Olson et al.  
5,019,088 A 5/1991 Farr  
5,019,089 A 5/1991 Farr  
5,026,384 A 6/1991 Farr et al.  
5,062,384 A 11/1991 Foley et al.  
5,062,648 A 11/1991 Gomringer  
5,071,407 A 12/1991 Termin et al.  
5,098,440 A 3/1992 Hillstead  
5,100,386 A 3/1992 Inoue  
5,100,423 A 3/1992 Fearnot  
5,101,682 A 4/1992 Radisch et al.  
5,102,402 A 4/1992 Dror et al.  
5,102,417 A 4/1992 Palmaz  
5,108,416 A 4/1992 Ryan et al.  
5,112,345 A 5/1992 Farr  
5,116,318 A 5/1992 Hillstead  
5,120,322 A 6/1992 Davis et al.  
5,133,732 A 7/1992 Wiktor  
5,176,693 A 1/1993 Pannek et al.  
5,181,911 A 1/1993 Shturman

(Continued)

**FOREIGN PATENT DOCUMENTS**

CN 1688350 A 10/2005  
EP 0565796 B1 5/1997

(Continued)

**OTHER PUBLICATIONS**

Notification of the First Office Action dated Jan. 16, 2014, from corresponding CN application No. 201080066293.3.

Cremers et al. Comparison of Two Different Paclitaxel-Coated Balloon Catheters in the Porcine Coronary Restenosis Model; Clin Res Cardiol (2009) 98:325-350; DOI 10.1007/s00392-009-0008-2.

European search report and search opinion dated May 4, 2010 for EP 06770116.9.

European search report and search opinion dated Dec. 28, 2009 for EP 05792875.6.

Extended European Search Report issued in EP Application No. 11827369.7, mailed Apr. 7, 2014. 6 pages.

File History for U.S. Appl. No. 11/411,635, filed Apr. 26, 2006.

(Continued)

*Primary Examiner* — Hasan Ahmed

(74) *Attorney, Agent, or Firm* — Faegre Baker Daniels LLP

(57) **ABSTRACT**

The present invention is related to scoring or cutting balloon catheters carrying at least on a portion of their surface at least one drug or drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one lipophilic antioxidant in relation to 100% by weight of the drug, wherein a combination of the at least one drug being a limus drug and the at least one lipophilic antioxidant being butylated hydroxytoluene is excluded.

**20 Claims, No Drawings**

(56)

## References Cited

## U.S. PATENT DOCUMENTS

5,190,058 A	3/1993	Jones et al.	5,746,716 A	5/1998	Vigil et al.
5,192,291 A	3/1993	Pannek et al.	5,746,968 A	5/1998	Radisch et al.
5,196,024 A	3/1993	Barath	5,755,708 A	5/1998	Segal
5,199,951 A	4/1993	Spears	5,755,778 A	5/1998	Kleshinski
5,209,727 A	5/1993	Radisch et al.	5,755,781 A	5/1998	Jayaraman
5,221,261 A	6/1993	Termin et al.	5,766,201 A	6/1998	Ravenscroft et al.
5,221,727 A	6/1993	Kumpf et al.	5,766,238 A	6/1998	Lau et al.
5,222,971 A	6/1993	Willard et al.	5,772,681 A	6/1998	Leoni
5,224,945 A	7/1993	Pannek et al.	5,776,141 A	7/1998	Klein et al.
5,224,949 A	7/1993	Gomringer et al.	5,776,181 A	7/1998	Lee et al.
5,226,887 A	7/1993	Farr et al.	5,779,698 A	7/1998	Clayman et al.
5,243,997 A	9/1993	Uflacker et al.	5,792,144 A	8/1998	Fischell et al.
5,263,963 A	11/1993	Garrison et al.	5,792,415 A	8/1998	Hijlkema
5,295,493 A	3/1994	Radisch et al.	5,797,935 A	8/1998	Barath
5,295,959 A	3/1994	Gurbel et al.	5,800,450 A	9/1998	Lary et al.
5,304,121 A	4/1994	Sahatjian	5,807,355 A	9/1998	Ramzipoor et al.
5,306,250 A	4/1994	March et al.	5,810,767 A	9/1998	Klein
5,308,354 A	5/1994	Zacca et al.	5,814,061 A	9/1998	Osborne et al.
5,308,356 A	5/1994	Blackshear, Jr. et al.	5,827,321 A	10/1998	Roubin et al.
5,318,576 A	6/1994	Plassche et al.	5,863,284 A	1/1999	Klein
5,320,634 A	6/1994	Vigil et al.	5,868,708 A	2/1999	Hart et al.
5,336,178 A	8/1994	Kaplan et al.	5,868,719 A	2/1999	Tsukernik
5,336,234 A	8/1994	Vigil et al.	5,868,779 A	2/1999	Ruiz
5,344,401 A	9/1994	Radisch et al.	5,868,783 A	2/1999	Tower
5,344,419 A	9/1994	Spears	5,869,284 A	2/1999	Cao et al.
5,350,101 A	9/1994	Godlewski	5,873,852 A	2/1999	Vigil et al.
5,354,279 A	10/1994	Hofling	5,891,090 A	4/1999	Thornton
5,370,614 A	12/1994	Amundson et al.	5,893,840 A	4/1999	Hull et al.
5,376,077 A	12/1994	Gomringer	5,902,475 A	5/1999	Trozero et al.
5,419,777 A	5/1995	Hofling	5,904,679 A	5/1999	Clayman
5,423,745 A	6/1995	Todd et al.	5,904,698 A	5/1999	Thomas et al.
5,443,078 A	8/1995	Uflacker	5,906,639 A	5/1999	Rudnick et al.
5,443,446 A	8/1995	Shturman	5,916,166 A	6/1999	Reiss et al.
5,443,496 A	8/1995	Schwartz et al.	5,919,200 A	7/1999	Stambaugh et al.
5,449,372 A	9/1995	Schmaltz et al.	5,954,742 A	9/1999	Osypka
5,449,373 A	9/1995	Pinchasik et al.	5,961,490 A	10/1999	Adams
5,456,666 A	10/1995	Campbell et al.	5,967,984 A	10/1999	Chu et al.
5,456,667 A	10/1995	Ham et al.	5,980,486 A	11/1999	Enger
5,458,568 A	10/1995	Racchini et al.	5,987,661 A	11/1999	Peterson
5,460,607 A	10/1995	Miyata et al.	5,994,667 A	11/1999	Merdan et al.
5,470,314 A	11/1995	Walinsky	6,004,295 A	12/1999	Langer et al.
5,501,694 A	3/1996	Ressemann et al.	6,013,055 A	1/2000	Bampos et al.
5,524,635 A	6/1996	Uflacker et al.	6,036,686 A	3/2000	Griswold
5,527,282 A	6/1996	Segal	6,036,689 A	3/2000	Tu et al.
5,536,178 A	7/1996	Novelli	6,036,708 A	3/2000	Sciver
5,538,504 A	7/1996	Linden et al.	6,048,356 A	4/2000	Ravenscroft et al.
5,545,132 A	8/1996	Fagan et al.	6,053,913 A	4/2000	Tu et al.
5,556,405 A	9/1996	Lary	6,059,811 A	5/2000	Pinchasik et al.
5,556,408 A	9/1996	Farhat	6,071,285 A	6/2000	Lashinski et al.
5,562,620 A	10/1996	Klein et al.	6,071,286 A	6/2000	Mawad
5,569,195 A	10/1996	Saab	6,077,298 A	6/2000	Tu et al.
5,571,086 A	11/1996	Kaplan et al.	RE36,764 E	7/2000	Zacca et al.
5,571,523 A	11/1996	Lee et al.	6,102,904 A	8/2000	Vigil et al.
5,607,442 A	3/1997	Fischell et al.	6,106,548 A	8/2000	Roubin et al.
5,609,574 A	3/1997	Kaplan et al.	6,117,104 A	9/2000	Fitz
5,616,149 A	4/1997	Barath	6,117,153 A	9/2000	Lary et al.
5,620,457 A	4/1997	Pinchasik et al.	6,123,718 A	9/2000	Tu et al.
5,624,433 A	4/1997	Radisch et al.	6,129,706 A	10/2000	Janacek
5,628,746 A	5/1997	Clayman	6,129,708 A	10/2000	Enger
5,628,755 A	5/1997	Heller et al.	6,136,011 A	10/2000	Stambaugh
5,643,210 A	7/1997	Iacob	6,146,323 A	11/2000	Fischell
5,649,941 A	7/1997	Lary	6,152,944 A	11/2000	Holman et al.
5,681,281 A	10/1997	Vigil et al.	6,156,254 A	12/2000	Andrews et al.
5,690,642 A	11/1997	Osborne et al.	6,156,265 A	12/2000	Sugimoto
5,695,469 A	12/1997	Segal	6,165,187 A	12/2000	Reger
5,697,944 A	12/1997	Lary	6,190,356 B1	2/2001	Bersin
5,697,971 A	12/1997	Fischell et al.	6,190,403 B1	2/2001	Fischell et al.
5,702,410 A	12/1997	Klunder et al.	6,193,686 B1	2/2001	Estrada et al.
5,707,385 A	1/1998	Williams	6,197,013 B1	3/2001	Reed et al.
5,713,863 A	2/1998	Vigil et al.	6,203,569 B1	3/2001	Wijay
5,713,913 A	2/1998	Lary et al.	6,206,910 B1	3/2001	Berry et al.
5,730,698 A	3/1998	Fischell et al.	6,210,392 B1	4/2001	Vigil et al.
5,733,303 A	3/1998	Israel et al.	6,211,247 B1	4/2001	Goodman
5,735,816 A	4/1998	Lieber et al.	6,224,625 B1	5/2001	Jayaraman
5,742,019 A	4/1998	Radisch et al.	6,235,043 B1	5/2001	Reiley et al.
			6,241,762 B1	6/2001	Shanley
			6,245,040 B1	6/2001	Inderbitzen et al.
			6,258,087 B1	7/2001	Edwards et al.
			6,258,108 B1	7/2001	Lary

(56)

## References Cited

## U.S. PATENT DOCUMENTS

6,261,319	B1	7/2001	Kveen et al.	6,942,680	B2	9/2005	Grayzel et al.
6,280,411	B1	8/2001	Lennox	6,951,566	B2	10/2005	Lary
6,283,947	B1	9/2001	Mirzaee	7,011,654	B2	3/2006	Dubrul et al.
6,283,951	B1	9/2001	Flaherty et al.	7,011,670	B2	3/2006	Radisch et al.
6,287,336	B1	9/2001	Globerman et al.	7,029,483	B2	4/2006	Schwartz
6,289,568	B1	9/2001	Miller et al.	7,060,051	B2	6/2006	Palasis
6,296,651	B1	10/2001	Lary et al.	7,108,684	B2	9/2006	Farnan
6,299,604	B1	10/2001	Ragheb et al.	7,131,981	B2	11/2006	Appling et al.
6,306,151	B1	10/2001	Lary	7,172,609	B2	2/2007	Radisch et al.
6,306,166	B1	10/2001	Barry et al.	7,186,237	B2	3/2007	Meyer et al.
6,309,414	B1	10/2001	Rolando et al.	7,232,432	B2	6/2007	Fulton et al.
6,312,459	B1	11/2001	Huang et al.	7,303,572	B2	12/2007	Melsheimer et al.
6,319,229	B1	11/2001	Kim et al.	7,354,445	B2	4/2008	Nicholson et al.
6,319,230	B1	11/2001	Palasis et al.	7,357,813	B2	4/2008	Burgermeister
6,319,242	B1	11/2001	Patterson et al.	7,396,358	B2	7/2008	Appling et al.
6,319,251	B1	11/2001	Tu et al.	7,445,792	B2	11/2008	Toner
6,325,779	B1	12/2001	Zedler	7,445,795	B2	11/2008	Bakhshaei et al.
6,325,813	B1	12/2001	Hektner	7,455,652	B2	11/2008	Laird
6,332,880	B1	12/2001	Yang et al.	7,465,311	B2	12/2008	Wang et al.
6,355,013	B1	3/2002	van Muiden	7,494,497	B2	2/2009	Weber
6,355,059	B1	3/2002	Richter et al.	7,517,352	B2	4/2009	Evans et al.
6,361,545	B1	3/2002	Macoviak et al.	7,524,319	B2	4/2009	Dubrul
6,364,856	B1	4/2002	Ding et al.	7,566,319	B2	7/2009	McAuley et al.
6,371,961	B1	4/2002	Osborne et al.	7,686,824	B2	3/2010	Konstantino et al.
6,394,995	B1	5/2002	Solar et al.	7,691,119	B2	4/2010	Farnan
6,415,009	B1	7/2002	Toporov et al.	7,708,748	B2	5/2010	Weisenburgh, II et al.
6,416,494	B1	7/2002	Wilkins	7,708,753	B2	5/2010	Hardert
6,416,539	B1	7/2002	Hassdenteufel	7,736,375	B2	6/2010	Crow
6,419,692	B1	7/2002	Yang et al.	7,763,043	B2	7/2010	Goodin et al.
6,425,882	B1	7/2002	Vigil	7,780,715	B2	8/2010	Shaked et al.
6,425,908	B2	7/2002	Ravenscroft et al.	7,780,798	B2	8/2010	Stinson et al.
6,440,158	B1	8/2002	Saab	7,803,149	B2	9/2010	Bates et al.
6,447,501	B1	9/2002	Solar et al.	7,811,622	B2	10/2010	Bates et al.
6,450,988	B1	9/2002	Bradshaw	7,875,284	B2	1/2011	Reyes et al.
6,450,989	B2	9/2002	Dubrul et al.	7,931,663	B2	4/2011	Farnan et al.
6,454,775	B1	9/2002	Demarais et al.	7,955,350	B2	6/2011	Konstantino et al.
6,471,979	B2	10/2002	New et al.	7,963,942	B2	6/2011	Chen
6,475,233	B2	11/2002	Trozera	7,976,557	B2	7/2011	Kunis
6,475,234	B1	11/2002	Richter et al.	7,998,184	B2	8/2011	Eidenschink
6,475,236	B1	11/2002	Roubin et al.	8,043,259	B2	10/2011	Radisch et al.
6,478,807	B1	11/2002	Foreman et al.	8,052,703	B2	11/2011	St. Martin et al.
6,500,186	B2	12/2002	Lafontaine et al.	8,066,726	B2	11/2011	Kelley
6,515,099	B2	2/2003	Sato et al.	8,080,026	B2	12/2011	Konstantino et al.
6,517,765	B1	2/2003	Kelley	8,123,770	B2	2/2012	Olsen et al.
6,540,722	B1	4/2003	Boyle et al.	8,192,675	B2	6/2012	Burton et al.
6,551,310	B1	4/2003	Ganz et al.	8,221,444	B2	7/2012	Wang et al.
6,554,795	B2	4/2003	Bagaoisan et al.	8,323,307	B2	12/2012	Hardert
6,562,062	B2	5/2003	Jenusaitis et al.	8,348,987	B2	1/2013	Eaton
6,565,528	B1	5/2003	Mueller	8,382,820	B2	2/2013	Addonizio et al.
6,569,180	B1	5/2003	Sirhan et al.	8,454,637	B2	6/2013	Aggerholm et al.
6,575,993	B1	6/2003	Yock	8,574,248	B2	11/2013	Kassab
6,592,548	B2	7/2003	Jayaraman	8,673,387	B2	3/2014	Bates et al.
6,602,281	B1	8/2003	Klein	8,685,050	B2	4/2014	Schur et al.
6,605,107	B1	8/2003	Klein	8,685,990	B2	4/2014	Coats et al.
6,607,442	B2	8/2003	Ogata et al.	9,011,896	B2	4/2015	Speck et al.
6,613,072	B2	9/2003	Lau et al.	2001/0001113	A1	5/2001	Lim et al.
6,616,650	B1	9/2003	Rowe	2001/0001823	A1	5/2001	Ryan
6,616,678	B2	9/2003	Nishtala et al.	2001/0007082	A1	7/2001	Dusbabek et al.
6,626,861	B1	9/2003	Hart et al.	2001/0012950	A1	8/2001	Nishtala et al.
6,632,231	B2	10/2003	Radisch et al.	2001/0016753	A1	8/2001	Caprio et al.
6,648,912	B2	11/2003	Trout et al.	2002/0010487	A1	1/2002	Evans et al.
6,652,548	B2	11/2003	Evans et al.	2002/0010489	A1	1/2002	Grayzel et al.
6,656,156	B2	12/2003	Yang et al.	2002/0029015	A1	3/2002	Camenzind et al.
6,656,351	B2	12/2003	Boyle	2002/0037358	A1	3/2002	Barry et al.
6,663,660	B2	12/2003	Dusbabek et al.	2002/0038144	A1	3/2002	Trout et al.
6,682,545	B1	1/2004	Kester	2002/0045930	A1	4/2002	Burg et al.
6,695,813	B1	2/2004	Boyle et al.	2002/0065548	A1	5/2002	Birdsall et al.
6,730,064	B2	5/2004	Ragheb et al.	2002/0091438	A1	7/2002	Trozera
6,743,196	B2	6/2004	Barbut et al.	2002/0111633	A1	8/2002	Stoltze et al.
6,746,463	B1	6/2004	Schwartz	2002/0165599	A1	11/2002	Nasralla
6,783,542	B2	8/2004	Eidenschink	2002/0193873	A1	12/2002	Brucker et al.
6,840,950	B2	1/2005	Stanford et al.	2003/0018376	A1	1/2003	Solar et al.
6,872,206	B2	3/2005	Edwards et al.	2003/0023200	A1	1/2003	Barbut et al.
6,918,920	B1	7/2005	Wang et al.	2003/0028235	A1	2/2003	McIntosh et al.
6,939,320	B2	9/2005	Lennox	2003/0032973	A1	2/2003	Jenusaitis et al.
				2003/0065381	A1	4/2003	Solar et al.
				2003/0074046	A1	4/2003	Richter
				2003/0078606	A1	4/2003	Lafontaine et al.
				2003/0097169	A1	5/2003	Brucker et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2003/0105509	A1	6/2003	Jang et al.
2003/0114915	A1	6/2003	Mareiro et al.
2003/0144683	A1	7/2003	Sirhan et al.
2003/0149468	A1	8/2003	Wallsten
2003/0152870	A1	8/2003	Huang
2003/0153870	A1	8/2003	Meyer et al.
2003/0171799	A1	9/2003	Lee et al.
2003/0187494	A1	10/2003	Loaldi
2003/0195609	A1	10/2003	Berenstein et al.
2003/0199970	A1	10/2003	Shanley
2003/0199988	A1	10/2003	Devonec et al.
2003/0208244	A1	11/2003	Stein et al.
2003/0208255	A1	11/2003	O'Shaughnessy et al.
2004/0034384	A1	2/2004	Fukaya
2004/0106975	A1	6/2004	Solovay et al.
2004/0111108	A1	6/2004	Farnan
2004/0127475	A1	7/2004	New et al.
2004/0133223	A1	7/2004	Weber
2004/0143287	A1	7/2004	Konstantino et al.
2004/0193257	A1	9/2004	Wu et al.
2004/0208985	A1	10/2004	Rowan et al.
2004/0210299	A1	10/2004	Rogers et al.
2004/0230293	A1	11/2004	Yip et al.
2004/0243158	A1	12/2004	Konstantino et al.
2005/0010278	A1	1/2005	Vardi et al.
2005/0021070	A1	1/2005	Feld et al.
2005/0021071	A1	1/2005	Konstantino et al.
2005/0033417	A1	2/2005	Borges et al.
2005/0037048	A1	2/2005	Song
2005/0070888	A1	3/2005	DiMatteo et al.
2005/0080478	A1	4/2005	Barongan
2005/0083768	A1	4/2005	Hara
2005/0119723	A1	6/2005	Peacock
2005/0131512	A1	6/2005	Vonderwalde
2005/0137690	A1	6/2005	Salahieh et al.
2005/0271844	A1	12/2005	Mapes et al.
2005/0278021	A1	12/2005	Bates et al.
2005/0288629	A1	12/2005	Kunis
2006/0004323	A1	1/2006	Chang et al.
2006/0015133	A1	1/2006	Grayzel et al.
2006/0020243	A1	1/2006	Speck et al.
2006/0074484	A1	4/2006	Huber
2006/0085025	A1	4/2006	Farnan et al.
2006/0111736	A1	5/2006	Kelley
2006/0112536	A1	6/2006	Herweck et al.
2006/0129093	A1	6/2006	Jackson
2006/0149308	A1	7/2006	Melsheimer et al.
2006/0173487	A1	8/2006	Ufflacker et al.
2006/0184191	A1	8/2006	O'Brien
2006/0240014	A1	10/2006	Sukhatme
2006/0247674	A1	11/2006	Roman
2006/0259005	A1	11/2006	Konstantino et al.
2006/0259062	A1	11/2006	Konstantino
2006/0270193	A1	11/2006	Hidaka et al.
2007/0020380	A1	1/2007	Ding
2007/0037739	A1	2/2007	Wang et al.
2007/0112422	A1	5/2007	Dehdashtian
2007/0128242	A1	6/2007	Zhao
2007/0185513	A1	8/2007	Woolfson et al.
2007/0190103	A1	8/2007	Hossainy et al.
2007/0198047	A1	8/2007	Schon et al.
2007/0212394	A1	9/2007	Reyes et al.
2007/0213808	A1	9/2007	Roubin et al.
2008/0021385	A1	1/2008	Barry et al.
2008/0118544	A1	5/2008	Wang
2008/0181927	A1	7/2008	Zhao
2008/0241215	A1	10/2008	Falotico et al.
2008/0300610	A1	12/2008	Chambers
2009/0105686	A1	4/2009	Snow et al.
2009/0105687	A1	4/2009	Deckman et al.
2009/0136560	A1	5/2009	Bates et al.
2009/0246252	A1	10/2009	Arps et al.
2009/0246253	A1	10/2009	Ding
2009/0264859	A1	10/2009	Mas
2009/0281490	A1	11/2009	McAuley et al.
2009/0306582	A1	12/2009	Granada et al.
2010/0042121	A1	2/2010	Schneider et al.
2010/0121372	A1	5/2010	Farnan
2010/0179647	A1	7/2010	Carpenter et al.
2010/0209472	A1	8/2010	Wang
2010/0233228	A1	9/2010	Speck
2010/0233236	A1	9/2010	Zhao
2010/0278997	A1	11/2010	Speck et al.
2010/0285085	A1	11/2010	Stankus et al.
2010/0286720	A1	11/2010	Shaked et al.
2010/0286721	A1	11/2010	Goodin et al.
2010/0324645	A1	12/2010	Stankus et al.
2011/0054396	A1	3/2011	Kangas et al.
2011/0082483	A1	4/2011	Diamant et al.
2011/0125247	A1	5/2011	Farnan et al.
2011/0143014	A1	6/2011	Stankus et al.
2011/0160756	A1	6/2011	Aggerholm et al.
2011/0196340	A1	8/2011	Barry et al.
2011/0230818	A1	9/2011	Kunis
2011/0264039	A1	10/2011	Thielen et al.
2011/0270177	A1	11/2011	Chambers et al.
2011/0295200	A1	12/2011	Speck et al.
2012/0059401	A1	3/2012	Konstantino et al.
2012/0172787	A1	7/2012	McClain et al.
2012/0215251	A1	8/2012	Burton et al.
2012/0239001	A1	9/2012	Barry et al.
2012/0277626	A1	11/2012	Burbank et al.
2013/0023817	A1	1/2013	Speck et al.
2013/0041315	A1	2/2013	Speck
2013/0041391	A1	2/2013	Spencer et al.
2013/0041399	A1	2/2013	Hardert
2013/0046237	A1	2/2013	Speck et al.
2013/0060127	A1	3/2013	Burton et al.
2013/0066346	A1	3/2013	Pigott
2013/0096604	A1	4/2013	Hanson et al.
2013/0150874	A1	6/2013	Kassab
2013/0211381	A1	8/2013	Feld
2013/0218181	A1	8/2013	Feld et al.
2013/0231638	A1	9/2013	Speck et al.
2013/0338572	A1	12/2013	Speck
2014/0058358	A1	2/2014	Kassab
2014/0066960	A1	3/2014	Feld et al.
2014/0128801	A1	5/2014	Speck
2014/0188036	A1	7/2014	Speck
2014/0257181	A1	9/2014	Speck

## FOREIGN PATENT DOCUMENTS

EP	0623315	B1	6/1999
EP	1169970	A1	1/2002
EP	1179323	A2	2/2002
EP	0832608	B1	3/2003
EP	1042997	B1	3/2005
EP	1581298	B1	8/2006
EP	1414373	B1	5/2008
EP	1337198	B1	6/2009
EP	1748816	B1	7/2010
EP	2063924	B1	10/2010
EP	2283890	A1	2/2011
EP	1962696	B1	3/2012
EP	1737530	B1	3/2013
EP	2564890	A1	3/2013
JP	2002126086	A	5/2002
JP	2002126086	A1	5/2002
JP	2004148013	A1	5/2004
JP	2008504059	A	5/2005
WO	WO9102494	A1	3/1991
WO	9217118	A1	10/1992
WO	WO9301753	A2	2/1993
WO	WO9410919	A1	5/1994
WO	9423787	A1	10/1994
WO	WO9423787	A1	10/1994
WO	WO9424946	A1	11/1994
WO	WO9503083	A1	2/1995
WO	WO9805377	A1	2/1998
WO	WO9845506	A1	10/1998
WO	9917680	A1	4/1999
WO	9955253	A1	11/1999
WO	9962430	A1	12/1999

(56)

**References Cited**

## FOREIGN PATENT DOCUMENTS

WO	02076509	A2	10/2002
WO	02083011	A1	10/2002
WO	WO02083011	A1	10/2002
WO	WO03026536	A1	4/2003
WO	WO03039628	A2	5/2003
WO	WO03041760	A2	5/2003
WO	2004022124	A1	3/2004
WO	2004028582	A1	4/2004
WO	WO2004028610	A2	4/2004
WO	WO2004060460	A2	7/2004
WO	WO2004066852	A2	8/2004
WO	2004108130	A1	12/2004
WO	WO2005025458	A1	3/2005
WO	2006007173	A1	1/2006
WO	2009018816	A2	2/2009
WO	2009066330	A1	5/2009

## OTHER PUBLICATIONS

File History for U.S. Appl. No. 13/044,425, filed Mar. 9, 2011.  
 File History for U.S. Appl. No. 13/842,080, filed Mar. 15, 2013.  
 First Examination Report dated Feb. 5, 2014 from corresponding EP Application No. 05733012.8.  
 International search report and written opinion dated Feb. 27, 2007 for PCT/US2006/017872.

International search report and written opinion dated May 23, 2006 for PCT /2005/009571.

International search report and written opinion dated Jul. 26, 2007 for PCT/2005/028809.

International search report and written opinion dated Nov. 4, 2004 for PCT/2004/000177.

International Search Report and Written Opinion issued in PCT/US2011/052392 mailed Jan. 11, 2012, 7 pages.

International Search Report issued in PCT/US2002/035547 dated May 20, 2003, 3 Pages.

International Search Report issued in PCT/US2004/027836 dated Dec. 30, 2004, 1 Page.

Japanese office action dated Jul. 9, 2010 for JP 2007-505113. (in Japanese with English translation).

Scheller et al. Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis; Circulation. 2004;110:810-814, Aug. 9, 2004.

Supplementary European Search Report dated Nov. 20, 2013 from corresponding EP Application No. 05733012.8.

EP Examination Report dated Oct. 9, 2013 from corresponding EP Application No. 10775805.4, 6 pages.

International Search Report and Written Opinion issued in PCT Application No. PCTEP2010066754 Mailed May 1, 2011, 11 pages.

Notification of Office Action dated Aug. 14, 2014 from corresponding JP Application No. 2013-505347.

Suzuki et al. Anti-Oxidants for Therapeutic Use: Why Are Only a Few Drugs in Clinical Use? Advanced Drug Delivery Reviews, vol. 61, 2009, pp. 287-289.

# COATING FORMULATIONS FOR SCORING OR CUTTING BALLOON CATHETERS

## CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of PCT Application No. PCT/EP2011/056179, filed Apr. 18, 2011, which claims the benefit of EP Application No. 10160347.0, filed Apr. 19, 2010, the full disclosures of which are incorporated herein by reference in their entirety.

## BACKGROUND

### 1. Field of the Invention

The invention relates to the transfer of a drug loosely adhering to the surface of a scoring or cutting balloon catheter to a site inside the body, usually in a diseased blood vessel. The preferred application is local drug therapy during percutaneous transluminal angioplasty (PTA) or percutaneous transluminal coronary angioplasty (PTCA). The interventions are performed to restore blood flow in stenotic or occluded blood vessels, usually into arteries. A catheter is introduced in a major artery. At the distal end the catheter carries a cylindrical balloon in folded state with very small diameter and additional tools or structures which scratch or cut the luminal surface of the treated blood vessel or tissue. In the folded state the balloon can enter or pass the stenotic or occluded segment of e.g. a blood vessel. Once positioned in the narrowed segment, the balloon is inflated to enlarge the lumen of the blood vessel to its original diameter. Simultaneously, a drug may be transferred to the vessel wall to prevent early and late re-narrowing due to hyperproliferation of the injured vessel wall.

Medical devices may contain drugs either to improve the tolerance, efficacy or in vivo life-time of the device or the device serves as carrier for the drug. In any case the dosedensity (e.g. mg drug/mg device or mg drug/mm<sup>2</sup> device surface), chemical stability, adherence, release rate, and total amount released are important and frequently critical features of the drug formulation. These properties are the more critical the more the requirements during production and application of the device vary or may even be contradictory. Drug-coated angioplasty catheters are typical examples: the drug coating must adhere firmly to tolerate mechanical stress during production including folding of balloons, crimping of stents, packaging, transportation to customers, and during final application, which involves the passage through a narrow hemostatic valve, an introductory sheath or guiding catheter and a variable distance through possibly tortuous and narrow blood vessels. When the balloon is inflated the drug should be released within a minute or less as rapidly and as completely as possible. The problem was demonstrated by Cremers et al. (Cremers B, Biedermann M, Mahnkopf D, Bohm M, Scheller B. Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol 2009; 98:325-330) who retrieved as much as 50% of the dose from balloons after expansion for one minute in coronary arteries of pigs, whereas other catheters coated with the same drug and dose but in a different formulation released more than 95%. Almost perfect results (i.e., loss of only 10% of dose and residual drug on the balloon after expansion in an artery of about 10%) were achieved with a rigid prototype balloon (Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating—a novel method for prevention and therapy of restenosis. Circulation 2004; 110: 810-814). The application of the same coating

composition to more flexible modern balloon catheters resulted in problems, i.e., larger premature loss of the drug. The coating of scoring or cutting balloons with drugs in a reliable way with a dose which sufficient to be efficacious imposes additional problems because of the more complex structure of the device and the more complex production process.

### 2. Prior Art

Protection from premature drug release. Premature release of a drug from a balloon is a major problem which has been addressed by a variety of methods. Some of them are mechanical, e.g. the use of protection tubes, sleeves, envelopes. Examples are U.S. Pat. No. 5,370,614, USP 6,306,166, and U.S. Pat. No. 6,616,650 disclosing various protective sheaths which are retracted before the balloon is inflated, or U.S. Pat. No. 6,419,692 proposing a cover which bursts during balloon expansion. A different approach is taken in U.S. Pat. No. 5,893,840 disclosing structured balloon membranes with tiny cavities, WO 94/23787 with roughened balloon membranes to enhance the adherence of coating, or more recently U.S. Pat. No. 7,108,684 proposing a pouch which protects the drug-containing layer on the balloon and WO 2009/066330 disclosing methods placing the drug selectively under the folds of a folded balloon. Although efficacious these methods have the disadvantage of increasing the complexity and cost of production or make handling of the devices more difficult or add to the diameter of the devices (which must be kept as small as possible to facilitate passage through stenotic lesions). In some embodiments the protective membranes or perforated membranes interfere with the scoring components of the balloons or prevent a homogeneous transfer of the drug to the tissue or even put the patient at risk. None of these methods has been applied to scoring or cutting balloons and nothing is known about problems which will arise from the increasing complexity and mechanical problems arising from a disturbance of the protecting envelopes by the scoring or cutting structures and vice-versa.

Other approaches use either physical or chemical methods to control the release of drugs from a balloon surface, e.g. U.S. Pat. No. 5,304,121 describes a hydrogel which releases the drug only after exposure to a triggering agent; U.S. Pat. No. 5,199,951 relies on thermal activation; according to U.S. Pat. No. 7,445,792 a lipophilic "hydration inhibitor" protects water-soluble drugs from premature release; and according to U.S. Pat. No. 5,370,614 a viscous matrix protects the drug from premature release, however, the viscous matrix must be protected by a sheath during the passage to the stenotic vessel segment. None of the methods has been tested in practice and proven to fulfill the requirements for fast, reliable and complete drug transfer to the target tissue. None of the methods has been designed to be used with scoring or cutting balloons.

Numerous methods of sustained drug release are known and successfully used in practice but are not applicable to medical devices which are in contact with the target tissue for only a few seconds or minutes. Sustained drug release is usually achieved by embedding the drug in a polymer which restricts the diffusion rate to the surface and in this way controls the transfer into the adjacent tissue.

Therefore, a need remains for a method or formulation which protects the coating from premature losses during production, handling, and on the way to the lesion and still allows the immediate and complete release of the active ingredient at a location and point in time determined by the user. During the production process this problem is even more severe for scoring and cutting balloons because of the more complex structure of the product. Scoring and cutting balloons have merits in the treatment of certain lesions, e.g. if the conven-

tional smooth balloons tend to dislocate during inflation or if a controlled and predetermined injury of the vessel wall is preferred to an uncontrolled dissection during balloon inflation. Nevertheless, the problem of renarrowing of the vessel lumen due to excessive neointimal proliferation as a reaction to the unavoidable injury during dilatation is the same as with conventional balloon catheters.

An advantageous way to control adherence and release of a drug from a medical device, e.g., an angioplasty balloon, is the selection of a suitable formulation and coating which do not require mechanical protection, or additional physical or chemical interaction with the coating except the usual operation of the device e.g. inflation of a folded balloon to induce the release of the drug. Although desirable and frequently tried, the conflicting objectives of perfect adherence during production and before use and immediate release at the site of action make it a difficult task. A large variety of patent applications vaguely disclose measures, compositions and devices to solve this problem for conventional balloon catheters either by the selection of drugs, the choice of specific coating processes or formulations containing various additives. Long lists of compounds have been copied from textbooks of chemistry, pharmacology, or pharmacy but even with extensive experimentation disclosures are not sufficiently clear to allow a person familiar with the subject and skilled in the art to come to a satisfactory solution without an inventive step. Examples of prior art are US 2008/0118544 reciting an excessive number of substances and substance classes or U.S. Pat. No. 7,445,795 which discloses the use of hydration inhibitors' not applicable to the preferred class of very lipophilic drugs which require 'hydration enhancers' as e.g. disclosed in WO 2004/028582. Although the hydrophilic additives (which may be regarded as 'hydration enhancer') work quite well on certain conventional balloon membranes (Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating—a novel method for prevention and therapy of restenosis. *Circulation* 2004; 110: 810-814) the adherence to various modern conventional or scoring PTA or PTCA balloons is either too weak or too tight resulting in premature loss of a major proportion of the drug or incomplete release at the target site. None of the known compositions has been tried on scoring or cutting balloon catheters.

Prior art: Antioxidants. In theory, antioxidants address an almost universal feature of diseased tissue, namely the Reactive oxygen species', and should have widespread medical applications. In practice, only very few controlled clinical trials have shown beneficial effects of antioxidants (Suzuki K. Antioxidants for therapeutic use: Why are only a few drugs in clinical use? *Advanced Drug Delivery Reviews* 2009;61:287-289). Antioxidants are mentioned as potentially useful drugs for the treatment of focal vascular disease such as stenosis, restenosis, atherosclerotic plaques, and vulnerable plaques in US 2009/0136560 with no additive, in U.S. Pat. No. 5,571,523 as agents inducing apoptosis in vascular smooth muscle cells, in WO 2004/022124 either as active drugs or as 'hydration inhibitors'. In US 2008/0241215 probucol, a drug approved for the treatment of hyperlipidemia, a known risk factor for atherosclerosis, is proposed as the active ingredient in stent coating, either alone or combined with rapamycin or another anti-restenotic agent in a slow-release formulation. None of the above-mentioned documents contains data encouraging the use as additives to a lipophilic drug to delay the release rate of the drug and no specific compositions are disclosed which address the above-mentioned problems of adhesion of a drug before the target lesion is reached and immediate release when required.

Small proportions of antioxidants are commonly used to protect drugs or nutrients from decomposition by oxygen or oxidation, an application which has also been proposed for drugs coated on implantable medical devices such as stents (US 2007/0020380, US 2009/0246253) or balloon catheters (US 2009/0246252, especially paragraph [105]). However, antioxidants are commonly used in proportions of less than 1% by weight in relation to 100% by weight of the drug. Normally it is intended to use as less antioxidant as possible, i.e., less than 0.1% by weight in relation to 100% by weight of the drug (Voigt R. *Lehrbuch der pharmazeutischen Technologie*. 5. Edition, Verlag Chemie, Weinheim—Deerfield Beach, Florida—Basel, 1984).

Present invention. The problem underlying the present invention was the provision of a scoring or cutting balloon catheter with an improved adherence of the drug without negative effect on the release of the drug at the target site.

The problem was solved by a scoring or cutting balloon catheter according to claim 1. In other words, the problem was solved by a scoring or cutting balloon catheter carrying at least on a portion of its surface at least one drug or drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one lipophilic antioxidant in relation to 100% by weight of the drug, wherein a combination of limus drugs with butylated hydroxytoluene as the lipophilic antioxidant is excluded. Preferred embodiments are disclosed in the dependant claims.

During testing of a large variety of coating methods, additives and drug combinations the surprising discovery was made that certain lipophilic antioxidants added to even more lipophilic and less water soluble drugs in a defined mass ratio significantly increase the adherence of the drug to scoring and cutting balloons during handling and on the way to the target lesion even if the target lesion is located far away from the site where the device first enters a blood-filled introductory sheath, guiding catheter or vessel containing rapidly flowing blood. This was also tested with scoring balloons. In spite of the additional mechanical stress (as compared to conventional balloons) imposed on the coating due to the movement of the scoring wires surrounding the folded balloons the loss of the drug during the passage through a narrow hemostatic valve and a 3 curved guiding catheter was very low. Thus, at least one lipophilic antioxidant in an amount of 3-100% by weight is used as an adherence improver for drugs coated on a scoring or cutting balloon catheter. The wording "at least one lipophilic antioxidant" means that single antioxidants but also mixtures of different antioxidants are included.

Preferred examples of active drugs are inhibitors of cell proliferation, preferably taxanes such as paclitaxel, docetaxel and protaxel, immunosuppressants belonging to the class of substances binding to the mammalian target of rapamycin (mTOR), i.e., mTOR inhibitors such as sirolimus, everolimus, zotarolimus, biolimus and temsirolimus, most preferred is sirolimus, referred to as limus-drugs. Alternatively, specific inhibitors of neovascularization such as thalidomide, statins like atorvastatin, cerivastatin, flu-vastatin or anti-inflammatory drugs like corticoids or even more preferred lipophilic derivatives of corticoids such as betamethasone dipropionate or dexamethasone -21-palmitate. Various drugs may be applied or combined if different pharmacological actions are required or efficacy or tolerance is to be improved. Thus, the wording "at least one drug or drug preparation" means that single drugs but also mixtures of different drugs are included. Preferred drugs are either lipophilic (partition coefficient between n-butanol and water >10, or display very poor water solubility (<1 mg/ml, 20° C.).

Preferred additives to the active drugs are lipophilic antioxidants, particularly preferred are antioxidants which are solid at temperatures up to 40° C. Preferred are butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguaiaric acid, propyl gallate and ascorbyl palmitate. Probu-  
col is not a preferred additive. The combination of mTOR-binding limus-drugs with butylated hydroxytoluene is excluded as already mentioned above. This applies to combinations of the single drug with the single antioxidant as well as to combinations of butylated hydroxytoluene with mixtures consisting of different Limus drugs.

Lipophilic antioxidant means that the partition coefficient of the antioxidant between n-butanol and water is >1, more preferred >10 and even more preferred >100.

Preferably, the drug is more lipophilic than the antioxidant, i.e., the partition coefficient between n-butanol and water of the drug is higher than the partition coefficient between n-butanol and water of the antioxidant.

At the dose density used the chosen antioxidants do not display relevant therapeutic or prophylactic effects in respect of the disease which is treated by the coated medical device nor is the relative amount of the antioxidant chosen to protect the drug from oxidative decomposition. The dose density and the mass relation of the antioxidant to the drug are solely optimized in respect of adherence of the drug to and release from the medical device surface. The antioxidant dose on the medical device is too low to provide the desired pharmacological effect, i.e., it is ineffective on its own. The antioxidant on the medical device is not required to protect the active drug (e.g., the antiproliferative drug) from oxidative decomposition during production, sterilization and storage; at least it is not required at the dose or concentration applied according to this invention. 'Not required' means that the active drug is stable enough without the antioxidant or at an antioxidant dose or dose density or ratio to the active drug below the dose according to the present invention. 'Sufficient stability' means that less than 5% of the active drug is lost due to oxidative decomposition between the coating of the device and the use in patients one year after production if stored at ambient temperature (=drug or drug preparation stable against oxidative decomposition).

The dose of the antioxidant on the surface of a medical device may be defined in respect of the therapeutic drug. Preferred relationships (weight/weight) are 3-100% antioxidant of the weight of the drug. For example, if the dose density of the drug is 5 µg/mm<sup>2</sup> device surface, the amount of antioxidant is 0.15-5.0 µg/mm<sup>2</sup>. Higher proportions of the antioxidant may be selected if either the drug is applied at a dose below 3 µg/mm<sup>2</sup> device surface or the adherence of the drug to the device surface is further improved. The antioxidant load of the device may reach 10 µg/mm<sup>2</sup>. A higher load is possible. Other preferred ranges for the relationship of antioxidant to drug on a weight/weight basis are 5-100%, more preferred 10-100%, and even more preferred 20-100% in relation to 100% of the drug. The relationship may also be defined in respect of moles: in a preferred embodiment the antioxidant is present from 10 mole % relative to the drug to 200 mole %. Higher amounts of the antioxidant may be useful; they are only excluded if they display on their own significant pharmacological prophylactic or therapeutic effects in respect of the disease to be treated.

If more than one drug is used the total weight of the drugs or the total moles of the drugs serve as basis for the calculation of the amount of the antioxidant. If more than one antioxidant is used the total weight of the antioxidants or the total moles of the antioxidants serve as basis for the calculation of the amount of the antioxidants.

Polymer-free coating compositions are preferred. It is a special advantage of the present compositions that they do not require the use of polymers to prevent premature release of the drug.

Usually, drugs and mixtures of drugs with additives are coated on medical devices as liquid formulations in volatile solvents. The choice of solvent is important for the distribution of the drug on the device, especially if the device is coated at an advanced stage of production. An advanced stage of production of a scoring or cutting balloon may include the scoring or cutting elements of the device, the structures required to fix these elements and an already folded balloon. The solvents further determine the structure of the coating in dry state and the adherence and release of the drug from the surface. Preferred organic solvents are acetone, tetrahydrofuran, and various alcohols such as methanol and ethanol. Usually, 1 to 30% (volume/volume) water is added. The drug or drugs and the antioxidant may be applied at the same time dissolved in the same solvent or mixture of solvents. Alternatively, they may be separately dissolved in the same or different solvents and sequentially applied. In a preferred embodiment, the scoring or cutting balloon catheter has been coated with at least one drug and at least one antioxidant both together or each separately dissolved in tetrahydrofuran or a mixture of solvents containing more than 25% (v/v) tetrahydrofuran. Another preferred embodiment is based on a scoring or cutting balloon catheter, which has been coated with at least one drug and at least one antioxidant both together or each separately dissolved in acetone or a mixture of solvents containing more than 25% (v/v) acetone. Coating with dry particles such as micro- or nanoparticles, crystals, capsules etc. or particles suspended in a liquid preparation is possible. Coating with particles may be facilitated by a roughened or sticky surface of the medical device.

A variety of coating procedures providing more or less uniform layers on medical devices are known from the literature and are disclosed in patent applications. These include simple dipping, spraying, and methods providing precise doses and homogeneous distributions (e.g., WO 2009/018816). Coating may be applied stepwise, either as multiple layers of the same composition or as layers with different compositions e.g. the drug first and the antioxidant second or in the opposite order. All these methods may be applied to the formulations of the current invention. Furthermore, coated medical devices may be dried under different conditions such as temperature, air flow, gas composition, and pressure at different stages of the production process. They may be stored in water-vapor-tight seals with a separately packed water absorbing-agent within the seal.

Subject of the current invention are scoring or cutting balloon catheters, e.g., catheters for angioplasty or coronary angioplasty. Preferred are scoring or cutting balloon catheters for short-lasting use during an interventional image guided therapy. Short lasting use means that the device is not implanted but eliminated from the body when the procedure is finished, usually within less than 10 minutes, but never later than a few, preferably 5, hours after the end of the procedure. Catheters may contain balloon membranes made from various polymers and copolymers, polyamides (nylon 12, pebax), polyethylenes, polyurethanes, various polyvinyls and the like. Independently of the type of material, the adherence and release properties of drugs are improved by the addition of lipophilic antioxidants. Furthermore, catheters comprise elements which are aimed at scoring or cutting the surfaces in direct contact with the inflated balloons, e.g. wires with various profiles, or protrusions of the balloon surface.



7

The scoring or cutting balloon catheter carries the at least one drug or drug preparation and the at least one lipophilic antioxidant at least on a portion of its surface which is aimed at coming into close contact with the tissue to be treated, e.g., the balloon at the distal portion of a catheter shaft. This means that at least 5%, preferably more than 50%, most preferably more than 90% of the surface is coated. The balloon of a scoring or cutting balloon catheter has a central cylindrical part and two opposite conical ends. If less than 100% of the balloon catheter's surface is coated, it is preferred that the cylindrical part is coated and that at least parts of or the complete conical ends remain uncoated.

Below, the invention is described by means of Examples.

## EXAMPLE 1

Balloons for percutaneous transluminal coronary angioplasty type A (AngioSculpt 3.5 - 20 mm, AngioScore, Inc., Fremont Calif., USA) were coated either with paclitaxel alone or combined with iopromide (iodinated contrast agent according to WO 02/076509) or different amounts of butylated hydroxy-toluene (BHT); solvent: acetone/ethanol/H<sub>2</sub>O. Coated balloons were tested in respect of paclitaxel loss during the passage through a hemostatic valve, Medtronic Launcher JL 3.5 6F guiding catheter and one minute in stirred blood (37° C.). When admixed at sufficient concentration to the coating solution, BHT improved the adhesion of paclitaxel.

Coating solution	Catheter labeling	Loss on the way to the lesion % of dose
No additive	1	24
	2	40
Iopromide as an additive; ca. 0.5 mg/mg	3	49
paclitaxel	4	34
BHT 5% = 0.05 mg BHT/mg paclitaxel	5	15
	6	26
BHT 24% = 0.24 mg BHT/ mg paclitaxel	7	10
	8	6

## EXAMPLE 2

Balloons for percutaneous transluminal coronary angioplasty type A were coated either with paclitaxel alone or combined with iopromide (iodinated contrast agent according to WO 02/076509), see example 2, or butylated hydroxy-toluene (BHT) or nordihydroguaiaretic acid. Coated balloons were tested in respect of paclitaxel loss during the passage through a hemostatic valve, a Medtronic Launcher JL 3.5 6F guiding catheter and in stirred blood (37° C.) for one minute. When admixed at sufficient concentration to the coating solution, lipophilic antioxidants improve the adhesion of paclitaxel whereas the release during balloon inflation in a coronary artery (determined in separate experiments) was not impaired.

Coating solution	Labeling	Loss on the way to the lesion % of dose	Residual paclitaxel on balloons % of dose
No additive	Control	32	no data
acetone/ethanol/H <sub>2</sub> O	1, 2		

8

-continued

Coating solution	Labeling	Loss on the way to the lesion % of dose	Residual paclitaxel on balloons % of dose
Iopromide as an additive; ca. 0.5 mg/mg paclitaxel; acetone/ ethanol/H <sub>2</sub> O	Control 3, 4	42	~10
BHT 24% = 0.24 mg BHT/ mg paclitaxel; acetone/ethanol/H <sub>2</sub> O	A	15.3 ± 9.5	11
BHT 24% = 0.24 mg BHT/ mg paclitaxel; tetrahydrofuran/ ethanol/H <sub>2</sub> O	B	3.4 ± 4.8	13
Nordihydroguaiaretic acid 35% = 0.35 mg/mg paclitaxel; acetone/ ethanol/H <sub>2</sub> O	C	4.2 ± 7.2	no data

What is claimed is:

1. A scoring or cutting balloon catheter carrying at least on a portion of a surface of the scoring or cutting balloon catheter a coating composition comprising at least one drug or drug preparation and at least one lipophilic antioxidant that will protect the drug from premature loss during delivery to the angioplasty site and that is 3-100% by weight of the at least one drug or drug preparation, wherein the at least one drug or drug preparation is selected from the group consisting of a Limus drug, a cell proliferation inhibitor, and an inhibitor of neovascularization, the at least one lipophilic antioxidant is selected from the group consisting of butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguaiaretic acid, ascorbyl palmitate, and propyl gallate, and wherein a combination of a Limus drug with butylated hydroxytoluene as the lipophilic antioxidant is excluded.
2. The scoring or cutting balloon catheter according to claim 1 wherein the at least one lipophilic antioxidant is contained at a ratio of 5-100% by weight in relation to 100% by weight of the at least one drug or drug preparation.
3. The scoring or cutting balloon catheter according to claim 1, wherein the at least one drug or drug preparation is more lipophilic than the antioxidant.
4. The scoring or cutting balloon catheter according to claim 1, wherein the at least one drug or drug preparation is a Limus drug.
5. The scoring or cutting balloon catheter according to claim 1, wherein the at least one drug or drug preparation is a cell proliferation inhibitor.
6. The scoring or cutting balloon catheter according to claim 1, wherein the at least one drug or drug preparation is an inhibitor of neovascularization.
7. The scoring or cutting balloon catheter according to claim 1, wherein the at least one antioxidant load is up to 10 µg/mm<sup>2</sup> of coated catheter surface.
8. The scoring or cutting balloon catheter according to claim 1, which has been coated with the at least one drug or drug preparation and the at least one lipophilic antioxidant both together or each is separately dissolved in tetrahydrofuran or a mixture of solvents containing more than 25% (v/v) tetrahydrofuran.
9. The scoring or cutting balloon catheter according to claim 1, which has been coated with the at least one drug or drug preparation and the at least one lipophilic antioxidant both together or each is separately dissolved in acetone or a mixture of solvents containing more than 25% (v/v) acetone.

9

10. The scoring or cutting balloon catheter according to claim 1 wherein the at least one lipophilic antioxidant is contained at a ratio of 10-100% by weight in relation to 100% by weight of the at least one drug.

11. The scoring or cutting balloon catheter according to claim 1 wherein the at least one lipophilic antioxidant is contained at a ratio of 20-100% by weight in relation to 100% by weight of the at least one drug.

12. The scoring or cutting balloon catheter according to claim 1, wherein the at least one drug or drug preparation is a taxane.

13. The scoring or cutting balloon catheter according to claim 1, wherein the at least one drug or drug preparation is stable against oxidative decomposition and the at least one drug or drug preparation is selected from the group consisting of paclitaxel, protaxel, and docetaxel.

14. The scoring or cutting balloon catheter according to claim 1, wherein the at least one drug or drug preparation is stable against oxidative decomposition and the at least one drug or drug preparation is paclitaxel.

10

15. The scoring or cutting balloon catheter according to claim 14, wherein the at least one lipophilic antioxidant is nordihydroguaiaretic acid.

16. The scoring or cutting balloon catheter according to claim 1, wherein the at least one lipophilic antioxidant is nordihydroguaiaretic acid.

17. The scoring or cutting balloon catheter according to claim 1, wherein the coating composition is polymer-free.

18. The scoring or cutting balloon catheter according to claim 15, wherein the coating composition is polymer-free.

19. The scoring or cutting balloon catheter according to claim 1, wherein the at least one lipophilic antioxidant is selected from the group consisting of butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguaiaretic acid, and propyl gallate.

20. The scoring or cutting balloon catheter according to claim 1, wherein the at least one lipophilic antioxidant is selected from the group consisting of nordihydroguaiaretic acid and propyl gallate.

\* \* \* \* \*

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 9,173,977 B2  
APPLICATION NO. : 13/628627  
DATED : November 3, 2015  
INVENTOR(S) : Speck et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the title page

Item (56), under “OTHER PUBLICATIONS”, in Column 2, Line 11, delete “2014.” and insert -- 2014, --

On Page 5, Item (56), under “OTHER PUBLICATIONS”, in Column 2, Line 23, delete “PCTEP2010066754” and insert -- PCT/EP2010/066754 --

In the specification

In Column 1, Lines 37-38, delete “dosedensity” and insert -- dose density --

In Column 2, Line 43, delete “^hydration” and insert -- ‘hydration --

In Column 3, Line 30, delete “hydration” and insert -- ‘hydration --

In Column 3, Line 32, delete “^hydration” and insert -- ‘hydration --

In Column 3, Line 34, delete “^hydration” and insert -- ‘hydration --

In Column 3, Line 59, delete “atheriosclerosis,” and insert -- atherosclerosis, --

In Column 4, Line 1, delete “antioxidantsare” and insert -- antioxidants are --

In Column 4, Line 6, delete “[105 ]).” and insert -- [105]). --

In Column 4, Line 28, delete “claims .” and insert -- claims. --

In Column 4, Line 57, delete “flu-vastatin” and insert -- fluvastatin --

Signed and Sealed this  
Twentieth Day of December, 2016



Michelle K. Lee  
*Director of the United States Patent and Trademark Office*

**CERTIFICATE OF CORRECTION (continued)**

Page 2 of 2

**U.S. Pat. No. 9,173,977 B2**

In Column 4, Line 60, delete “dipropionate” and insert -- dipropionate --

In Column 5, Line 3, delete “buty-lated” and insert -- butylated --

In Column 5, Lines 4-5, delete “nordihydroguaiaretic” and insert -- nordihydroguaiaretic --

In Column 6, Line 32, delete “nanoparticles ,” and insert -- nanoparticles, --

In Column 6, Line 60, delete “copolymers , polyam-ides” and insert -- copolymers, polyamides --

In Column 7, Line 23, delete “ $_2\text{O}$ .” and insert --  $\text{H}_2\text{O}$ . --

In Column 7, Line 50, delete “nordihydroguaj aretic” and insert -- nordihydroguaiaretic --